References

  1. Simeon-Dubach D, Zeisberger S M, Hoerstrup S P. Quality Assurance in Biobanking for Pre-Clinical Research. Transfus Med Hemother 2016;43(5):353-357.
  2. Yu K K, Zhang J, Li X, et al. Establishment and management of a lung cancer biobank in Eastern China. Thoracic Cancer 2015;58–63.
  3. Fachiroh J, Dwianingsih E K, Wahdi A E, et al. Development of a Biobank from a Legacy Collection in Universitas Gadjah Mada, Indonesia: Proposed Approach for Centralized Biobank Development in Low-Resource Institutions. Biopreserv Biobank 2019.
  4. Chen Z, Chen J, Collins R, et al. China Kadoorie Biobank of 0.5 million people: survey methods, baseline characteristics and long-term follow-up. Int J Epidemiol 2011;40(6):1652-66.
  5. Trehearne A. Genetics, lifestyle and environment. UK Biobank is an open access resource following the lives of 500,000 participants to improve the health of future generations. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2016;59(3):361-7.
  6. Holub P, Swertz M, Reihs R, et al. BBMRI-ERIC Directory: 515 Biobanks with Over 60 Million Biological Samples. Biopreserv Biobank 2016;14(6):559-562.
  7. Porteri C, Pasqualetti P, Togni E, et al. Public’s attitudes on participation in a biobank for research: an Italian survey. BMC Medical Ethics 2014;15:81.
  8. Bourgeois F T, Avillach P, Kong S W, et al. Development of the Precision Link Biobank at Boston Children’s Hospital: Challenges and Opportunities. J Pers Med 2017;7(4).
  9. Zawati M H, Tassé A M, Mendy M, et al. Barriers and Opportunities in Consent and Access Procedures in Low- and Middle-Income Country Biobanks: Meeting Notes from the BCNet Training and General Assembly. Biopreserv Biobank 2018;16(3):171-178.
  10. Quinlan P R, Mistry G, Bullbeck H, et al. A data standard for sourcing fit-for-purpose biological samples in an integrated virtual network of biobanks. Biopreserv Biobank 2014;12(3):184-91.
  11. Zhou Y T, Ge X T, Shen Y F, et al. Follow-up of the manganese-exposed workers healthy cohort (MEWHC) and biobank management from 2011 to 2017 in China. BMC Public Health 2018;18:944.
  12. Draanen G V, Davidson P, Bour-Jordan H, et al. Assessing Researcher Needs for a Virtual Biobank. Biopreserv Biobank 2017;15(3):203-210.
  13. Lacerda E M, Mudie K, Kingdon C C, et al. The UK ME/CFS Biobank: A Disease-Specific Biobank for Advancing Clinical Research Into Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Front Neurol 2018;9:1026.
  14. Henderson M K, Goldring K, Simeon-Dubach D, et al. Advancing Professionalization of Biobank Business Operations: Performance and Utilization. Biopreserv Biobank 2019;17(3):213-218.
  15. Hirata M, Kamatani Y, Nagai A, et al. Cross-sectional analysis of BioBank Japan clinical data: A large cohort of 200,000 patients with 47 common diseases. J Epidemiol 2017;27(3S):S9-S21.
  16. Grizzle W E, Sexton K C, McGarvey D, et al. Lessons Learned During Three Decades of Operations of Two Prospective Bioresources. Biopreserv Biobank 2018;16(6):483-492.